Skip to main content
Erschienen in: Rheumatology International 2/2021

28.10.2020 | Observational Research

Long-term follow-up of 89 patients with giant cell arteritis: a retrospective observational study on disease characteristics, flares and organ damage

verfasst von: Burak Ince, Selay Artan, Yasemin Yalcinkaya, Bahar Artim-Esen, Ahmet Gul, Lale Ocal, Murat Inanc

Erschienen in: Rheumatology International | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

The objective of the study is to investigate the clinical characteristics and long-term prognosis including flares and organ damage in patients with giant cell arteritis (GCA) from a tertiary referral centre and compare these features in different subgroups. In this retrospective observational study, patients with GCA who were followed up in our vasculitis clinic between 1998 and 2018 were evaluated by a predefined protocol. Patients with and without cranial symptoms were compared for clinical and laboratory features, flares and permanent damage findings. Vasculitis Damage Index and Large Vessel Vasculitis Index of Damage were used for damage assessment. Records of 89 patients (median follow-up time 46 months) were analysed; mean time to diagnosis after initial symptom was longer in patients with acute vision loss (11 ± 4 vs. 4.8 ± 1.1 months p = 0.002). EGG (n = 19) was younger (63 ± 2 vs. 69 ± 1 years old p = 0.01); had higher mean CRP (141.8 ± 107.3 vs. 76.6 ± 67.9 mg/dL p = 0.023) and ESR (120.8 ± 25.1 vs. 99.3 ± 24.3 mm/h p = 0.004) at diagnosis. PET–CT detected large vessel vasculitis in 42/48 (87.5%) cases of the entire cohort. Thirty-one patients had flares and proportion of flared patients was significantly higher in patients with cranial symptoms. At least one damage item (DI) was present in 54 (60.7%) patients. The development of damage was found to be associated with flares. Evaluation of our cohort revealed the importance of early diagnosis for prevention of vision loss in GCA. Patients without cranial symptoms were younger, present with higher inflammatory response and for these, PET–CT was the main diagnostic tool. Relapse rate was higher in patients with cranial symptoms. Flares and accompanying corticosteroid treatment may contribute to organ damage in GCA.
Literatur
1.
Zurück zum Zitat Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–11CrossRef Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–11CrossRef
2.
Zurück zum Zitat Gonzalez-gay MA, Vazquez-rodriguez TR, Lopez-diaz MJ, Miranda-filloy JA, Gonzalez-juanatey C, Martin J et al (2009) Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 61(10):1454–1461CrossRef Gonzalez-gay MA, Vazquez-rodriguez TR, Lopez-diaz MJ, Miranda-filloy JA, Gonzalez-juanatey C, Martin J et al (2009) Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 61(10):1454–1461CrossRef
3.
Zurück zum Zitat Brekke LK, Diamantopoulos AP, Fevang BT, Abetamus J, Espero E, Gjesdal CG (2017) Incidence of giant cell arteritis in Western Norway 1972–2012: a retrospective cohort study. Arthritis Res Ther 19(1):278CrossRef Brekke LK, Diamantopoulos AP, Fevang BT, Abetamus J, Espero E, Gjesdal CG (2017) Incidence of giant cell arteritis in Western Norway 1972–2012: a retrospective cohort study. Arthritis Res Ther 19(1):278CrossRef
4.
Zurück zum Zitat Gonzalez-gay MA, Miranda-filloy JA, Lopez-diaz MJ, Perez-alvarez R, Gonzalez-juanatey C, Sanchez-andrade A et al (2007) Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore) 86(2):61–68CrossRef Gonzalez-gay MA, Miranda-filloy JA, Lopez-diaz MJ, Perez-alvarez R, Gonzalez-juanatey C, Sanchez-andrade A et al (2007) Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore) 86(2):61–68CrossRef
5.
Zurück zum Zitat Pamuk ON, Donmez S, Karahan B, Pamuk GE, Cakir N (2009) Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: clinical features and epidemiological data. Clin Exp Rheumatol 27(5):830–833PubMed Pamuk ON, Donmez S, Karahan B, Pamuk GE, Cakir N (2009) Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: clinical features and epidemiological data. Clin Exp Rheumatol 27(5):830–833PubMed
6.
Zurück zum Zitat Salvarani C, Gabriel SE, O’fallon WM, Hunder GG (1995) The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 123(3):192–194CrossRef Salvarani C, Gabriel SE, O’fallon WM, Hunder GG (1995) The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 123(3):192–194CrossRef
7.
Zurück zum Zitat Kobayashi S, Yano T, Matsumoto Y, Numano F, Nakajima N, Yasuda K et al (2003) Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 49(4):594–598CrossRef Kobayashi S, Yano T, Matsumoto Y, Numano F, Nakajima N, Yasuda K et al (2003) Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 49(4):594–598CrossRef
8.
Zurück zum Zitat Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33(8):1122–1128CrossRef Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33(8):1122–1128CrossRef
10.
Zurück zum Zitat Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G (2016) The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford) 55(1):66–70CrossRef Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G (2016) The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford) 55(1):66–70CrossRef
11.
Zurück zum Zitat De Boysson H, Lambert M, Liozon E, Boutemy J, Maigne G, Ollivier Y et al (2016) Giant-cell arteritis without cranial manifestations: Working diagnosis of a distinct disease pattern. Medicine (Baltimore) 95(26):e3818CrossRef De Boysson H, Lambert M, Liozon E, Boutemy J, Maigne G, Ollivier Y et al (2016) Giant-cell arteritis without cranial manifestations: Working diagnosis of a distinct disease pattern. Medicine (Baltimore) 95(26):e3818CrossRef
12.
Zurück zum Zitat Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D et al (2017) Trial of Tocilizumab in giant-cell arteritis. New Engl J Med 377(4):317–328CrossRef Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D et al (2017) Trial of Tocilizumab in giant-cell arteritis. New Engl J Med 377(4):317–328CrossRef
13.
Zurück zum Zitat Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M et al (2016) The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess 20(90):1–238CrossRef Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M et al (2016) The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess 20(90):1–238CrossRef
14.
Zurück zum Zitat Hellmich B, Agueda A, Monti S, Buttgereit F, De Boysson H, Brouwer E, et al (2019) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis Hellmich B, Agueda A, Monti S, Buttgereit F, De Boysson H, Brouwer E, et al (2019) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis
16.
Zurück zum Zitat Broder MS, Sarsour K, Chang E, Collinson N, Tuckwell K, Napalkov P et al (2016) Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis. Semin Arthritis Rheum 46(2):246–252CrossRef Broder MS, Sarsour K, Chang E, Collinson N, Tuckwell K, Napalkov P et al (2016) Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis. Semin Arthritis Rheum 46(2):246–252CrossRef
17.
Zurück zum Zitat Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG et al (2001) A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19(5):495–501PubMed Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG et al (2001) A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19(5):495–501PubMed
18.
Zurück zum Zitat Mahr AD, Jover JA, Spiera RF, Hernandez-garcia C, Fernandez-Gutierrez B, Lavalley MP et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56(8):2789–2797CrossRef Mahr AD, Jover JA, Spiera RF, Hernandez-garcia C, Fernandez-Gutierrez B, Lavalley MP et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56(8):2789–2797CrossRef
19.
Zurück zum Zitat Catanoso M, Macchioni P, Boiardi L, Muratore F, Restuccia G, Cavazza A et al (2017) Incidence, prevalence, and survival of biopsy-proven giant cell arteritis in northern Italy during a 26-year period. Arthritis Care Res (Hoboken) 69(3):430–438CrossRef Catanoso M, Macchioni P, Boiardi L, Muratore F, Restuccia G, Cavazza A et al (2017) Incidence, prevalence, and survival of biopsy-proven giant cell arteritis in northern Italy during a 26-year period. Arthritis Care Res (Hoboken) 69(3):430–438CrossRef
20.
Zurück zum Zitat Salvarani C, Crowson CS, O’fallon WM, Hunder GG, Gabriel SE (2004) Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum. 51(2):264–268CrossRef Salvarani C, Crowson CS, O’fallon WM, Hunder GG, Gabriel SE (2004) Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum. 51(2):264–268CrossRef
21.
Zurück zum Zitat Vodopivec I, Rizzo JF (2018) 3RD. Ophthalmic manifestations of giant cell arteritis. Rheumatology (Oxford) 57(Suppl_2):ii63–ii72CrossRef Vodopivec I, Rizzo JF (2018) 3RD. Ophthalmic manifestations of giant cell arteritis. Rheumatology (Oxford) 57(Suppl_2):ii63–ii72CrossRef
22.
Zurück zum Zitat Li L, Neogi T, Jick S (2017) Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink. Rheumatology (Oxford) 56(5):753–762 Li L, Neogi T, Jick S (2017) Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink. Rheumatology (Oxford) 56(5):753–762
23.
Zurück zum Zitat Kermani TA, Sreih AG, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA et al (2018) Evaluation of damage in giant cell arteritis. Rheumatology (Oxford) 57(2):322–328CrossRef Kermani TA, Sreih AG, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA et al (2018) Evaluation of damage in giant cell arteritis. Rheumatology (Oxford) 57(2):322–328CrossRef
24.
Zurück zum Zitat Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO et al (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40(2):371–380CrossRef Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO et al (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40(2):371–380CrossRef
25.
Zurück zum Zitat Ehlers L, Askling J, Bijlsma HW, Cid MC, Cutolo M, Dasgupta B et al (2019) 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Ann Rheum Dis 78(9):1160–1166CrossRef Ehlers L, Askling J, Bijlsma HW, Cid MC, Cutolo M, Dasgupta B et al (2019) 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Ann Rheum Dis 78(9):1160–1166CrossRef
26.
Zurück zum Zitat Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C et al (2012) 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 64(4):943–954CrossRef Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C et al (2012) 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 64(4):943–954CrossRef
27.
Zurück zum Zitat Salvarani C, Pipitone N, Versari A, Hunder GG (2012) Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 8(9):509–521CrossRef Salvarani C, Pipitone N, Versari A, Hunder GG (2012) Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 8(9):509–521CrossRef
28.
Zurück zum Zitat Cunha BA, Lortholary O, Cunha CB (2015) Fever of unknown origin: a clinical approach. Am J Med 128(10):1138 ((e1–e15))CrossRef Cunha BA, Lortholary O, Cunha CB (2015) Fever of unknown origin: a clinical approach. Am J Med 128(10):1138 ((e1–e15))CrossRef
30.
Zurück zum Zitat Font C, Cid MC, Coll-vinent B, Lopez-soto A, Grau JM (1997) Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 36(2):251–254CrossRef Font C, Cid MC, Coll-vinent B, Lopez-soto A, Grau JM (1997) Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 36(2):251–254CrossRef
31.
Zurück zum Zitat Cid MC, Font C, Oristrell J, De la Sierra A, Coll-vinent B, Lopez-soto A et al (1998) Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 41(1):26–32CrossRef Cid MC, Font C, Oristrell J, De la Sierra A, Coll-vinent B, Lopez-soto A et al (1998) Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 41(1):26–32CrossRef
32.
Zurück zum Zitat Weyand CM, Tetzlaff N, Bjornsson J, Brack A, Younge B, Goronzy JJ (1997) Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 40(1):19–26CrossRef Weyand CM, Tetzlaff N, Bjornsson J, Brack A, Younge B, Goronzy JJ (1997) Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 40(1):19–26CrossRef
33.
Zurück zum Zitat Weyand CM, Younge BR, Goronzy JJ (2011) IFN-gamma and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol 23(1):43–49CrossRef Weyand CM, Younge BR, Goronzy JJ (2011) IFN-gamma and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol 23(1):43–49CrossRef
34.
Zurück zum Zitat Best JH, Kong AM, Unizony S, Tran O, Michalska M (2019) Risk of potential glucocorticoid-related adverse events in patients with giant cell arteritis: results from a USA-based electronic health records database. Rheumatol Ther 6(4):599–610CrossRef Best JH, Kong AM, Unizony S, Tran O, Michalska M (2019) Risk of potential glucocorticoid-related adverse events in patients with giant cell arteritis: results from a USA-based electronic health records database. Rheumatol Ther 6(4):599–610CrossRef
35.
Zurück zum Zitat Macchioni P, Boiardi L, Muratore F, Restuccia G, Cavazza A, Pipitone N et al (2019) Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study. Rheumatology (Oxford) 58(4):609–616CrossRef Macchioni P, Boiardi L, Muratore F, Restuccia G, Cavazza A, Pipitone N et al (2019) Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study. Rheumatology (Oxford) 58(4):609–616CrossRef
36.
Zurück zum Zitat Nesher G, Poltorak V, Hindi I, Nesher R, Dror Y, Orbach H et al (2019) Survival of patient with giant cell arteritis: impact of vision loss and treatment with aspirin. Autoimmun Rev 18(8):831–834CrossRef Nesher G, Poltorak V, Hindi I, Nesher R, Dror Y, Orbach H et al (2019) Survival of patient with giant cell arteritis: impact of vision loss and treatment with aspirin. Autoimmun Rev 18(8):831–834CrossRef
Metadaten
Titel
Long-term follow-up of 89 patients with giant cell arteritis: a retrospective observational study on disease characteristics, flares and organ damage
verfasst von
Burak Ince
Selay Artan
Yasemin Yalcinkaya
Bahar Artim-Esen
Ahmet Gul
Lale Ocal
Murat Inanc
Publikationsdatum
28.10.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 2/2021
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04730-1

Weitere Artikel der Ausgabe 2/2021

Rheumatology International 2/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.